Targeted drug extends survival of leukemia patients
Washington, Feb 27 (ANI): Patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments, experience long-term benefits when they switch to the targeted drug imatinib, according to a new study.
The finding indicates that imatinib is the treatment of choice for these patients.
Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and prognosis of patients with CML.
Now up to 93 percent of patients who take the drug as initial therapy for CML survive at least eight years, whereas prior to imatinib, patients survived an average of only three to six years.
While imatinib is now the standard drug given after a diagnosis of CML, approximately 15,000 to 20,000 patients in the United States may have started taking imatinib after failing to respond to the previous standard drug for CML, interferon.
Like patients who now take imatinib as initial therapy for their cancer, these patients seem to respond well to imatinib, at least in the short term; however, little is known about their long-term prognosis.
To investigate, Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center in Houston, and his colleagues analyzed 368 CML patients from their institution who started taking imatinib after failing to respond to interferon.
The team estimated that 68 percent of patients survived for at least 10 years. Previous research indicates that only 20 to 30 percent of patients who do not respond to interferon therapy and have no access to imatinib survive this long.
According to the authors, these findings suggest that most patients can benefit from imatinib after unsuccessful interferon treatments, and they do not have to consider other therapeutic options.
The study has been published online in Cancer, a peer-reviewed journal of the American Cancer Society. (ANI)
Read More: United Nations Volunteers | United nations | American Samoa | Gorakhpur University | Agra University | Ayurvedic University | Bundelkhand University So | Mds University Ajmer Dtso | United Salt Work | Daxini Society | Azad Society | Chandkheda Society Area | Ambika Society Kalol | Kalol Society Area | Patel Society Area Tso Nad | 3 Eme Center | Madanapalle Society Colony | Spinning Mills Center | Theosophical Society Gdsso | Cancer
Gault et Millau names Alleno cook of the year
October 22, 2014 at 7:55 PM
Rally against HK leader comments on poor people and democracy
October 22, 2014 at 7:50 PM
Protesters march to Hong Kong leader's home
October 22, 2014 at 7:40 PM
WHAT WAS CONG DOING FOR PAST 10 YEARS ON BLACK MONEY - BJP
October 22, 2014 at 7:19 PM
SECURITY IN VALLEY TIGHT AHEAD OF MODI VISIT
October 22, 2014 at 7:18 PM
CONG URGES JAITLEY TO STOP BEING A BLACKMAILER
October 22, 2014 at 7:17 PM